AI Article Synopsis
- A retrospective study in a pediatric intensive care unit assessed the impact of a risk stratified sedation weaning protocol on medication costs and patient outcomes over a two-year period.
- The results showed that implementing the protocol reduced total sedation weaning costs significantly from approximately $400,329 to around $170,459, with lower median costs per patient.
- Despite the cost reduction, the incidence of withdrawal symptoms before and after the protocol remained similar, indicating that patient outcomes were not adversely affected by the change.
Article Abstract
Objective: A risk stratified sedation weaning protocol improved patient outcomes in a pediatric intensive care unit (PICU). We sought to determine the protocol effect on medication costs.
Methods: This was a retrospective observational cohort study in an academic tertiary care children's hospital PICU (2018-2020) comparing the cost when weaning benzodiazepine, alpha agonist, and/or opioid infusions in intubated children <18 years of age.
Results: There were 84 total sedation weaning instances (pre-protocol n = 41 and post-protocol n = 41); 2 patients had 2 encounters, 1 in each phase. The total cost (in 2022 United States Dollars) of sedation weaning was $400,328.87 ($15,994.44/kg) pre-protocol compared with $170,458.85 ($11,227.52/kg) post-protocol. The median cost of sedation wean per patient for pre-protocol patients was $3197.42 (IQR: $322.66-$12,643.29) and post-protocol patients was $1851.44 (IQR: $425.05-$5355.85; p = 0.275). A linear regression model estimated the expected cost of sedation wean for post-protocol patients to be $5173.20 lower than for pre-protocol patients of the same weight and overall drug risk (p = 0.036). The proportion of withdrawal symptoms in the pre-protocol patients (16%) was not significantly different from the proportion in the post-protocol patients (14%; p = 0.435).
Conclusions: Implementation of a PICU sedation weaning protocol in a single-center conferred cost benefit without negatively impacting patient outcomes. A larger multicenter study would provide insight to the applicability to PICUs in varied settings with differing patient populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472412 | PMC |
| http://dx.doi.org/10.5863/1551-6776-29.5.501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges in Transitioning from Controlled to Assisted Ventilation in Acute Respiratory Distress Syndrome (ARDS) Management.
J Clin Med
December 2024
Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Centro de Ciências da Saúde, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha Do Fundão, Rio de Janeiro 21941-598, RJ, Brazil.
Acute respiratory distress syndrome (ARDS) presents significant challenges in critical care, primarily due to its inflammatory nature, which leads to impaired gas exchange and respiratory mechanics. While mechanical ventilation (MV) is essential for patient support, the transition from controlled to assisted ventilation is complex and may be associated with intensive care unit-acquired weakness, ventilator-induced diaphragmatic dysfunction and patient self-inflicted lung injury. This paper explores the multifaceted challenges encountered during this transition, with a focus on respiratory effort, sedation management, and monitoring techniques, and investigates innovative approaches to enhance patient outcomes.
View Article and Find Full Text PDFDevelopment and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessment Instrument for Monitoring Iatrogenic Withdrawal Symptoms in Children Receiving an Alpha-2 Agonist.
Pediatr Crit Care Med
January 2025
Department of Family and Community Health; School of Nursing, University of Pennsylvania, Philadelphia, PA.
Objectives: To develop and conduct preliminary testing of the Withdrawal Assessment Tool-Alpha 2 Agonist (WAT-A2A) to monitor dexmedetomidine and clonidine withdrawal symptoms in acutely ill children.
Design: Three-phase instrument development study. Phase 1: retrospective chart review of symptoms exhibited by children with documented dexmedetomidine withdrawal; phase 2: WAT-A2A instrument construction based on phase 1 data; and phase 3: prospective testing of the WAT-A2A in children weaning from alpha 2 agonists (A2As).
Right Drug in the Wrong Place: The Effects of Inadvertent Intrathecal Tranexamic Acid.
Cureus
October 2024
Anesthesiology, Unidade Local de Saúde da Região de Aveiro, Aveiro, PRT.
Tranexamic acid (TXA) is an antifibrinolytic drug widely used to reduce blood loss in major surgeries and trauma patients, thus reducing morbimortality. In recent years, clinical indications for TXA have expanded, including many off-label uses. This broad use has led to an increased incidence of reported side effects and administration errors with serious neurological and cardiovascular outcomes, such as seizures, myoclonus, and arrhythmias.
View Article and Find Full Text PDFNoise-sensitivity during sleep in non-sedated mechanically ventilated patients is associated with weaning duration: a polysomnographic study.
Sleep Breath
November 2024
INSERM, Clinical Investigation Center 1402, Research team Is-Alive, University of Poitiers, Faculty of Medicine and Pharmacy, Poitiers, France.
Background: Poor sleep is a major concern in intensive care units (ICUs), particularly in mechanically ventilated patients, because it is associated with longer duration of the weaning phase and higher mortality. High noise levels in ICUs are frequently reported by patients as one of the most disturbing sleep-disrupting factors but would be responsible for less than 20% of arousals. This suggests major inter-individual variability in noise sensitivity.
View Article and Find Full Text PDFTracheostomy: update on why, when and how.
Curr Opin Crit Care
February 2025
Adult Intensive Care Unit, University Hospital and University of Lausanne, Lausanne, Switzerland.
Article Synopsis
- The review discusses the importance of developing effective strategies for using tracheostomy in ICU patients needing extended mechanical ventilation or having airway protection issues.
- Recent findings highlight that tracheostomy can improve patient comfort, ease the weaning process, and help with recovery activities, although it doesn’t decrease mortality and may lead to complications like tracheal stenosis.
- An individualized approach is necessary to determine the optimal timing and technique for tracheostomy, favoring the percutaneous single dilator method with trained personnel when appropriate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!